2598 related articles for article (PubMed ID: 18450602)
1. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
6. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
[TBL] [Abstract][Full Text] [Related]
7. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
8. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
9. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
[TBL] [Abstract][Full Text] [Related]
10. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Muccioli G; Viola A; Pane F; Palmieri S
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1018-24. PubMed ID: 20172040
[TBL] [Abstract][Full Text] [Related]
11. Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Wakita S; Kanamori H; Usuki K; Uoshima N; Yanada M; Shono K; Ueki T; Mizuno I; Yano S; Takeuchi J; Kanda J; Okamura H; Inamoto Y; Inokuchi K; Fukuda T
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1125-1132. PubMed ID: 27040395
[TBL] [Abstract][Full Text] [Related]
12. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
13. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
14. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
Lu Y; Chen W; Chen W; Stein A; Weiss LM; Huang Q
Am J Hematol; 2010 Jun; 85(6):426-30. PubMed ID: 20513120
[TBL] [Abstract][Full Text] [Related]
15. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
16. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
[TBL] [Abstract][Full Text] [Related]
17. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
19. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
